Qol Holdings (3034) FY2027 Q1 Earnings Report

Quick View

Executive Summary

The quarter was characterized by higher revenue and earnings, as well as significant profit growth driven by an improvement in the gross margin. The most important point is that profit progress is ahead of the full-year plan. Revenue was ¥739.1B (+3.0% YoY), Operating Income was ¥61.8B (+72.1%), Ordinary Income was ¥61.6B (+69.5%), and Net Income attributable to owners of the parent was ¥30.0B (+61.7%). The gross margin improved to 17.6%, while the SG&A ratio declined to 9.3%, resulting in an expansion of the Operating Income margin to 8.4% (5.0% in the previous year). Although the Pharmaceutical Business’s higher margins drove company-wide earnings, the persistently high tax burden restrained Net Income growth.

Factors Affecting Business Performance

【Revenue】Revenue was ¥739.1B, representing a 3.0% YoY increase. By segment, the Pharmacy Business (HealthInsurancePharmacy) generated ¥437.5B ( +2.1%, 59.2% of total revenue), the Pharmaceutical Business generated ¥263.8B (+3.8%, 35.7%), and the BPO Business generated ¥42.2B (+11.3%, 5.7%). The BPO Business recorded a relatively high growth rate. Revenue from prescription fulfillment increased by ¥40.2B and remained the core source of revenue, while revenue from pharmaceutical manufacturing and sales also increased to ¥26.4B.

【Profit and Loss】Operating Income increased substantially to ¥61.8B (+72.1%), while Ordinary Income rose to ¥61.6B (+69.5%). The primary driver of earnings growth was the expansion of segment profit in the Pharmaceutical Business to ¥49.4B (+113.4%, 18.7% margin), making it the largest contributor to company-wide earnings. In contrast, despite higher revenue, the Pharmacy Business recorded lower profit of ¥16.7B (-4.7%, 3.8% margin), demonstrating a pattern of higher revenue but lower earnings. The BPO Business remained solid at ¥6.5B (+31.6%, 15.4% margin). Extraordinary items were extremely small, with extraordinary losses of ¥0.1B, and the impact of one-time factors was limited. Net Income was limited to ¥30.0B (+61.7%), with the decline from Ordinary Income attributable to the high tax burden (an effective tax rate of approximately 51%). Overall, the company achieved higher revenue and earnings.

Segment Analysis

Segment profit consisted of ¥16.7B for the Pharmacy Business (23.0% of total segment profit, 3.8% margin), ¥49.4B for the Pharmaceutical Business (68.1%, 18.7% margin), and ¥6.5B for the BPO Business (8.9%, 15.4% margin), with the Pharmaceutical Business accounting for approximately 70% of company-wide profit. Operating Income in the Pharmaceutical Business more than doubled, increasing 113.4% from slightly below ¥24.2B in the previous year, while its profit margin also rose substantially. Although revenue in the Pharmacy Business increased 2.1%, profit declined 4.7%, indicating margin pressure under the dispensing fee environment. The BPO Business achieved double-digit growth in both revenue and profit, recording the highest growth rate within the business mix. Company-wide expenses (adjustments) increased from ¥△16.9B in the previous year to ¥△17.9B, with the adjustment equivalent to 14.8% of total segment profit of ¥72.6B.

Key Financial Indicators

【Profitability】The Operating Income margin improved by +336bp to 8.4% (5.0% in the previous year), while the Ordinary Income margin improved to 8.3% (5.1% in the previous year), and the Net Income margin attributable to owners of the parent improved to 4.1% (2.6% in the previous year). The gross margin expanded to 17.6% (14.5% in the previous year), while the SG&A ratio declined to 9.3% (9.5% in the previous year), directly contributing to the improvement in the Operating Income margin. ROE was 6.0%.【Cash Flow Quality】Non-operating income was small at ¥1.7B, and extraordinary items were also insignificant, with extraordinary losses of ¥0.1B. The gap between Ordinary Income and Net Income was primarily attributable to corporate income taxes, and the impact of one-time factors was limited.【Investment Efficiency】The Equity Ratio was 37.6%, broadly unchanged from the previous year. Total assets increased to ¥1636.9B, while intangible fixed assets (¥684.1B, including goodwill of ¥353.7B) accounted for 41.8% of total assets, indicating a high concentration of assets derived from M&A.【Financial Soundness】Long-term borrowings were ¥183.8B and cash and deposits were ¥257.0B. Against interest expense of ¥1.1B, Operating Income of ¥61.8B indicates ample interest-servicing capacity. However, current assets of ¥667.1B compared with current liabilities of ¥795.2B indicate a somewhat tight short-term funding balance.

Cash Flow Analysis

Although detailed disclosure of the statement of cash flows is not available, funding trends can be inferred from changes in the balance sheet. Cash and deposits increased to ¥257.0B, while inventories increased substantially year on year, and accounts receivable and notes receivable remained broadly unchanged at ¥251.2B. Accounts payable and notes payable increased to ¥372.2B, suggesting the use of payment terms associated with expanded procurement. As the increase in inventories may place pressure on working capital, near-term cash generation is considered likely to depend on the turnover efficiency of inventories and accounts receivable. Long-term borrowings were ¥183.8B, broadly unchanged from the previous year, and large-scale financing or repayment activity was limited.

Quality of Earnings

The current period’s earnings growth was primarily driven by an improvement in core operating profit. Extraordinary items were extremely small, consisting of extraordinary income of ¥0.0B and extraordinary losses of ¥0.1B (loss on disposal of fixed assets), indicating that earnings quality is supported by improvement in recurring business activities. Non-operating income was ¥1.7B, including other income of ¥0.3B, compared with non-operating expenses of ¥1.9B, including interest expense of ¥1.1B and handling fees of ¥0.3B, resulting in a slight net excess of expenses. Comprehensive Income was ¥37.1B. The difference between Net Income of ¥30.0B and the ¥37.1B attributable to owners of the parent reflects the impact of ¥7.1B attributable to non-controlling interests. No factors such as valuation differences on securities were observed that would cause a material divergence between Net Income and Comprehensive Income, and no unusual accrual adjustments were identified. The decline from Ordinary Income of ¥61.6B to Net Income of ¥30.0B was primarily due to the corporate income tax burden, with an effective tax rate of approximately 51%. This should be noted as not being a temporary factor arising from the business structure.

Earnings Forecasts and Guidance

The full-year company plan calls for Revenue of ¥3150.0B (+8.3% YoY), Operating Income of ¥165.0B (+11.4%), and Ordinary Income of ¥165.0B (+10.9%). There were no revisions to either the earnings or dividend forecasts during the quarter. Progress rates were 23.5% for Revenue, 37.5% for Operating Income, and 37.3% for Ordinary Income, with progress in Operating Income and Ordinary Income substantially exceeding progress in Revenue. This reflects the high-margin contribution of the Pharmaceutical Business. Based on quarterly progress at this stage, upside to profit forecasts can be inferred, although the sustainability of the Pharmaceutical Business’s profitability throughout the full year will determine future progress.

Shareholder Returns

The company’s full-year dividend plan is ¥54 per share, representing an increase from the previous year’s annual dividend (the sum of interim and year-end dividends; reference data provides partial disclosure, including a previous-year dividend of ¥23). The Payout Ratio against the company’s planned EPS of ¥207.57 is approximately 26.0% (¥54 ÷ ¥207.57), a conservative level. No specific data regarding share repurchases was identified, and shareholder returns currently center on dividends. Given cash and deposits of ¥257.0B and the company’s earnings generation capacity for the current period, there are considered to be no major constraints on dividend sustainability.

Risk Factors

1. Pharmacy Business profitability stagnation: Against revenue growth of +2.1%, the Pharmacy Business recorded a 4.7% decline in Operating Income (3.8% margin), indicating continued margin pressure under the dispensing fee and drug pricing environment. Improving the profitability of this business will be a challenge for smoothing company-wide earnings.

2. Concentration in goodwill and intangible assets: Goodwill of ¥353.7B accounts for 57.5% of net assets of ¥615.4B, while intangible fixed assets of ¥684.1B account for 41.8% of total assets of ¥1636.9B. The high concentration of assets derived from M&A creates a structural impairment risk if business plans are not achieved.

3. High effective tax rate and impact on Net Income: Against Ordinary Income of ¥61.6B, Net Income attributable to owners of the parent was ¥30.0B, resulting in an effective tax rate of approximately 50%, a high level. The heavy tax burden is a structural factor restraining growth in Net Income and ROE.

Industry Benchmark (Reference; Company Analysis)

Industry Benchmark (retail)

Profitability and Returns

The Company’s Operating Income margin and Net Income margin both exceed the industry median, indicating that its profitability is relatively high within the industry.

Growth and Capital Efficiency

The Revenue growth rate is below the industry median, indicating that top-line growth is relatively moderate within the industry.

※Source: Company analysis

Key Points from the Financial Results

1. The Pharmaceutical Business’s higher margins lifted the company-wide Operating Income margin by +336bp, and profit progress against the full-year plan (37.5%) substantially exceeded Revenue progress (23.5%). The extent to which the Pharmaceutical Business’s earnings structure can be sustained will be a key focus going forward.

2. Although the Pharmacy Business achieved higher revenue, its profit margin declined to 3.8%, increasing earnings dependence on the Pharmaceutical Business. The widening margin differential within the business portfolio (18.7% for the Pharmaceutical Business versus 3.8% for the Pharmacy Business) represents an observable change in the earnings structure.

3. The asset composition, in which goodwill and intangible assets account for more than 40% of total assets, reflects an M&A-led growth strategy. At the same time, the persistently high effective tax rate continues to affect Net Income. These are structural characteristics relevant to assessing the quality of the financial results.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly disclosed data using a residual income model (Ohlson type, with an explicit five-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥1,788–¥1,895 at ±1% for the cost of equity, and ¥1,835–¥1,848 at ±0.1 for ω.

Notes:

• Because progress of Net Income against the full-year forecast (38%) exceeds the standard level (25%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies with progress ahead of plan tend to exceed forecasts. The adjustment may be excessive for businesses with strong seasonality).
• Net Income is substantially compressed relative to Operating Income due to the tax burden, acquisition-related expenses, and non-controlling interests (Net Income ÷ Operating Income 47%). This value reflects that compression at face value, and normalized earnings may be higher if the factors are temporary.
• Goodwill represents a high proportion of net assets, and the assumptions would change substantially if impairment occurred.
• Net assets at the end of the quarter are used, resulting in a timing difference relative to the full-year forecast.
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Model: Residual Income Model / Interest rate reference month: 2026-07 / This value is not intended to forecast or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with a professional advisor as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 was a strong earnings quarter, with modest revenue growth translating into a substantial recovery in operating and attributable profit. Revenue increased 3.0% year on year to ¥73.9bn. Operating income rose 72.1% to ¥6.18bn. Ordinary income increased 69.5% to ¥6.16bn. Profit attributable to owners of the parent rose 61.7% to ¥3.00bn, equivalent to EPS of ¥79.90. The operating margin expanded to 8.4% from 5.0% a year earlier, a 336bp improvement. Gross margin improved to 17.6% from 14.5%, a 314bp expansion, and was the principal driver of earnings growth. SG&A increased only 0.7%, substantially below revenue growth, reducing the SG&A-to-sales ratio by 21bp to 9.3%. The Pharmaceuticals segment was the main earnings engine, with segment profit more than doubling to ¥4.94bn. BPO also delivered solid growth, while Pharmacy segment profit declined despite higher sales. The resulting profit mix is more dependent on pharmaceutical manufacturing and sales profitability than in the prior-year quarter. Q1 operating-income progress against the full-year forecast reached 37.5%, well above the standard 25% seasonal benchmark. Attributable-profit progress was also high at 38.5% of the full-year forecast. This creates scope for upside to the current plan if the Pharmaceuticals margin recovery persists, although the company has not revised its forecast. Financial leverage supported the annualized 19.5% ROE, but the balance sheet has a material concentration in goodwill and intangible assets. Liquidity remains structurally tight, with current liabilities exceeding current assets. The inventory increase warrants attention because it was much faster than revenue growth. The forecast dividend of ¥54 per share implies a conservative 26.0% payout ratio based on forecast EPS of ¥207.57.

Profitability Analysis

Annualized DuPont ROE is 19.5%, comprising a 4.1% net profit margin, 1.806x asset turnover, and 2.66x financial leverage. The strongest component in the quarter was the improvement in profit margin: operating margin rose 336bp year on year to 8.4%, while gross margin expanded 314bp to 17.6%. This indicates that gross-profit improvement, rather than sales growth alone, was the central earnings driver. SG&A grew only ¥0.49bn, or 0.7%, versus a ¥2.18bn, or 3.0%, increase in sales, generating positive operating leverage. The Pharmaceuticals segment was the core business by segment-profit contribution, generating ¥4.94bn of segment profit, or 68.1% of aggregate segment profit before corporate costs. Pharmaceuticals revenue increased 3.8% to ¥26.38bn and segment profit rose 113.4%, lifting its segment margin to 18.7% from 9.1%. BPO revenue increased 10.1% to ¥3.84bn and segment profit grew 31.6% to ¥0.65bn; its segment margin improved to 15.4% from 13.0%. Pharmacy revenue rose 2.0% to ¥43.69bn, but segment profit fell 4.7% to ¥1.67bn, compressing its segment margin to 3.8% from 4.1%. Pharmacy remains the largest revenue contributor, but its weaker profitability contrasts with the sharp recovery in Pharmaceuticals. Corporate costs increased to ¥1.79bn from ¥1.69bn, partly offsetting segment-level earnings momentum. The 17.6% gross margin remains below the stated 20% quality-alert threshold, reflecting a relatively low-margin business mix; however, the 314bp improvement substantially strengthens the quarter's profitability profile. The supplied tax burden of 0.488, equivalent to a 51.2% effective burden on profit attributable to owners relative to profit before tax, is below the normal benchmark and constrained conversion from pre-tax profit to parent earnings. This metric is also affected by ¥0.71bn of profit attributable to non-controlling interests, but the low attributable-profit conversion remains relevant to shareholders. Interest burden was strong at 0.994 and interest coverage was 54.72x, indicating that financing costs did not materially dilute operating profit. Under JGAAP, goodwill amortization reduces operating income and net income relative to an IFRS reporter with otherwise similar acquired assets, making earnings comparability across accounting standards important.

Growth Assessment

Revenue growth of 3.0% was below the full-year forecast growth rate of 8.3%, but Q1 operating income growth of 72.1% substantially exceeded the full-year operating-income growth assumption of 11.4%. Q1 sales represented 23.5% of the ¥315.0bn full-year sales target, modestly below the standard 25% progress rate. Q1 operating income represented 37.5% of the ¥16.5bn full-year target, 12.5 percentage points above the standard Q1 run rate. Q1 ordinary income also represented 37.3% of the ¥16.5bn full-year forecast. Profit attributable to owners reached 38.5% of the ¥7.8bn full-year target. The gap between sales progress and profit progress indicates that forecast delivery depends more on sustaining margin normalization than on a simple extrapolation of Q1 revenue growth. Pharmaceuticals provides the greatest near-term earnings leverage given its 18.7% segment margin and ¥2.63bn year-on-year increase in segment profit. BPO's 10.1% sales growth and 31.6% profit growth provide a second source of expansion. In contrast, Pharmacy's 4.7% segment-profit decline makes recovery in pharmacy productivity, reimbursement conditions, and operating costs important to sustaining group growth. The absence of a forecast revision despite high Q1 profit progress suggests management may be retaining a prudent view on subsequent-quarter margins and business conditions. The FY2027 forecast assumes ¥16.5bn of operating income and ordinary income, with forecast EPS of ¥207.57.

Financial Health

Liquidity is a key balance-sheet risk. The current ratio is 0.84x and the quick ratio is 0.76x, both below 1.0x, while working capital is negative ¥12.81bn. Current assets of ¥66.71bn do not fully cover current liabilities of ¥79.52bn, creating a maturity mismatch that requires continued access to operating cash generation, supplier financing, and bank funding. Short-term loans are ¥12.0bn and represent 39.5% of interest-bearing debt. Cash and deposits of ¥25.70bn cover short-term loans by 2.14x, providing a useful immediate liquidity buffer despite the sub-1.0x current ratio. Interest-bearing debt totals ¥30.38bn, equivalent to a 1.66x debt-to-equity ratio. This is below the 2.0x aggressive-leverage warning threshold, and debt-to-capital of 33.1% remains within the stated sub-40% investment-grade benchmark. Interest coverage of 54.72x is strong and indicates low near-term debt-service pressure. Total equity increased ¥1.70bn year on year to ¥61.54bn, supported by earnings accumulation. Goodwill is ¥35.37bn, equal to 57.5% of equity and 21.6% of total assets. This exceeds the 50% goodwill-to-equity warning threshold and makes capital value sensitive to the performance and recoverable value of acquired businesses. Intangible assets total ¥68.41bn, or 41.8% of total assets, well above the 30% concentration warning threshold. The high intangible-asset concentration means a meaningful portion of the asset base is dependent on continued cash generation from acquired operations and other identifiable intangible assets. Goodwill decreased ¥1.05bn year on year and intangible assets decreased ¥1.55bn, consistent with ongoing amortization and/or asset consumption under JGAAP rather than a further build-up in these balances.

Notable B/S Changes

Inventories: +¥2.11bn (+45.8%) to ¥6.71bn - growth materially exceeded the 3.0% sales increase; monitor turnover, expiry/obsolescence exposure, and working-capital absorption.

Cash Flow Quality

Cash-flow quality cannot be quantified from the reported financial data in this period. The ¥2.10bn, or 45.8%, increase in inventories to ¥6.71bn was materially faster than 3.0% revenue growth and is the most important working-capital item to monitor. Using annualized Q1 cost of sales and average inventory, inventory turnover is approximately 4.3x and inventory days are approximately 85 days. The inventory build may reflect pharmaceutical manufacturing volumes, procurement timing, or anticipated demand, but it raises the importance of inventory sell-through and obsolescence control. Trade receivables declined 2.7% year on year to ¥25.12bn, which is favorable relative to revenue growth. Trade payables increased 14.1% to ¥37.22bn, partially supporting liquidity. The combined pattern of higher inventories and payables means that the durability of operating cash conversion should be assessed through subsequent-quarter cash flow and inventory movement. No conclusion on OCF-to-net-income conversion, free cash flow, capital-expenditure coverage, or cash conversion can be drawn from the available figures.

Dividend Sustainability

The full-year dividend forecast is ¥54 per share, with no revision announced. Based on forecast EPS of ¥207.57, the implied dividend payout ratio is 26.0%. This is well below the 60% sustainability benchmark and leaves substantial earnings retention capacity. Q1 EPS of ¥79.90 represents 38.5% of forecast EPS, consistent with the elevated Q1 attributable-profit progress rate. The conservative payout provides a buffer against volatility in Pharmaceuticals earnings, Pharmacy profitability, and any additional amortization or impairment pressure on acquisition-related assets. The dividend outlook is supported by forecast attributable profit of ¥7.8bn, although balance-sheet liquidity and working-capital needs remain relevant to cash distribution capacity. No share repurchase data is provided, so total return ratio is not assessed.

Risk Assessment

Business risks include Pharmacy profitability risk: Pharmacy segment revenue increased 2.0%, but segment profit declined 4.7% to ¥1.67bn, indicating sensitivity to reimbursement, dispensing volume, labor costs, and store-level productivity., Pharmaceuticals earnings-normalization risk: Pharmaceuticals segment profit increased 113.4% to ¥4.94bn and accounted for 68.1% of aggregate segment profit before corporate costs; a reversal in its 18.7% segment margin would have a material group impact., Healthcare policy and drug-price risk: Pharmacy dispensing and pharmaceutical manufacturing/sales earnings are exposed to reimbursement revisions, drug-price changes, generic-drug competition, quality-control requirements, and supply-chain disruptions., Inventory risk: Inventories increased 45.8% to ¥6.71bn, far above revenue growth, increasing exposure to demand timing, product expiry, markdowns, and working-capital absorption., Low gross-margin risk: Gross margin of 17.6% remains below the 20% alert threshold, leaving group profitability sensitive to procurement costs, product mix, reimbursement pricing, and operational inefficiency..

Financial risks include Low-liquidity risk: The 0.84x current ratio and negative ¥12.81bn working capital mean current liabilities exceed current assets, requiring disciplined management of cash, payables, inventory, and debt maturities., Goodwill risk: Goodwill of ¥35.37bn equals 57.5% of equity, above the 50% warning threshold; weaker acquired-business performance could increase impairment risk., Intangible-asset concentration: Intangible assets are ¥68.41bn, or 41.8% of assets, above the 30% warning threshold, increasing dependence on the recoverability of acquisition-related and other intangible assets., Tax-conversion risk: The supplied 0.488 tax burden indicates only 48.8% of pre-tax profit converted to parent attributable profit in Q1, limiting shareholder earnings conversion., Funding-cost risk: Debt-to-equity of 1.66x is manageable and interest coverage is strong, but the ¥30.38bn debt balance remains exposed to refinancing and interest-rate conditions..

Key concerns include Highest impact: sustainability of the Pharmaceuticals margin rebound, because it drove most of the year-on-year operating-profit increase., High likelihood and impact: maintaining Pharmacy profitability amid healthcare reimbursement and labor-cost pressures., High impact: impairment or lower returns on the sizeable goodwill and intangible-asset base., Moderate likelihood and impact: inventory growth converting into slower cash generation if demand or manufacturing turnover weakens., Ongoing monitoring priority: liquidity management given the sub-1.0x current and quick ratios, notwithstanding cash coverage of short-term loans..

Investment Implications

Key takeaways include Q1 earnings materially outperformed the pace implied by the full-year operating-profit and attributable-profit forecasts., Gross-margin expansion and restrained SG&A growth generated strong operating leverage, lifting operating margin by 336bp to 8.4%., Pharmaceuticals is the core profit contributor, while Pharmacy remains the largest sales business but posted lower segment profit., The balance sheet has manageable interest-service capacity but elevated acquisition-asset exposure, with goodwill/equity at 57.5% and intangibles/assets at 41.8%., The ¥54 forecast DPS implies a low 26.0% dividend payout ratio based on forecast EPS..

Metrics to watch include Pharmaceuticals segment margin versus the Q1 level of 18.7%, Pharmacy segment profit and margin, which were ¥1.67bn and 3.8% in Q1, Inventory level and annualized inventory days, approximately 85 days in Q1, Current ratio, quick ratio, cash balance, and short-term-debt coverage, Goodwill and intangible-asset trends, including any impairment charges, Operating-income progress relative to the ¥16.5bn full-year forecast, Attributable-profit conversion from profit before tax and the effective tax burden.

Regarding relative positioning, The company combines healthcare-service exposure with pharmaceutical manufacturing/sales earnings. Its annualized 19.5% ROE and 8.4% operating margin are supported by strong Q1 margin recovery and moderate balance-sheet leverage, while its sub-1.0x liquidity ratios and high acquisition-related asset concentration make cash conversion and acquired-business performance more important than for a less acquisitive healthcare operator.